# Brandon Rice

> Brandon Rice is the CEO and co-founder of Weave Bio, an AI-native regulatory software company. A bioinformatics-trained product leader who helped start Dovetail Genomics and later worked across diagnostics, CRISPR tools, and drug manufacturing, Rice has built his career around translating complex science into useful products. At Weave, that means turning regulatory dossiers from static, manually assembled documents into traceable, reusable systems while keeping expert judgment at the center.

- **Role:** CEO and Co-Founder at Weave Bio
- **Organizations:** Weave Bio, Resilience, Synthego, Freenome, Dovetail Genomics, University of California, Santa Cruz, National Center for Genome Resources
- **Nationality:** American
- **Education:** Master's degree; graduate work in bioinformatics, University of California, Santa Cruz, Bachelor of Science, University of New Mexico, New Mexico Tech
- **Known for:** Co-founded Dovetail Genomics and helped commercialize bioinformatics technology developed at UC Santa Cruz., Is a named inventor on patents covering methods for tagging nucleic acids for sequence assembly., Co-founded and leads Weave Bio as CEO.

## Career timeline

- **2009–2011** — Worked as a software engineer at the National Center for Genome Resources.
- **2011–2013** — Completed graduate work in bioinformatics at UC Santa Cruz, including research on Neanderthal-derived variation in modern humans.
- **2013** — Helped found Dovetail Genomics from technology developed in Richard Green’s UC Santa Cruz lab and joined the company.
- **2013–2017** — Led Dovetail Genomics through early business establishment, intellectual property development, research, operations, and product strategy, serving in roles including CEO, COO, and Head of Product Development and Strategy.
- **2018–2019** — Worked in scientific alliance management and product management at Freenome, a multi-omic cancer-detection company.
- **2019–2020** — Held product leadership roles at Synthego across software products and functional genomics.
- **2020–2023** — Served as Director of Product Management at Resilience, working in drug-manufacturing platforms.
- **2023** — Joined Weave as Head of Product and became Chief Product Officer and co-founder.
- **2024** — Weave publicly launched AutoIND and announced $10 million in seed funding co-led by Innovation Endeavors and Magnetic Ventures.
- **2025** — Became CEO of Weave Bio; the company partnered with Parexel and raised a $20 million Series A led by USVP, bringing total capital raised to $36 million.
- **2026** — Led Weave’s expansion into NDA workflows and global submissions and established a strategic advisory board spanning pharma, academia, regulation, and investment.

## Achievements

- Co-founded Dovetail Genomics and helped commercialize bioinformatics technology developed at UC Santa Cruz.
- Is a named inventor on patents covering methods for tagging nucleic acids for sequence assembly.
- Co-founded and leads Weave Bio as CEO.
- Led product development around AutoIND and the broader Weave regulatory lifecycle platform.
- Helped secure a strategic design partnership with Parexel for AI-assisted regulatory submissions.
- Raised a $20 million Series A for Weave in 2025, bringing the company’s disclosed total funding to $36 million.
- Contributed to published work spanning structural variation detection and machine-learning-based cancer detection.
- Participated in a Weave-Takeda study reporting roughly 97% lower first-draft time for large nonclinical regulatory summaries.

## Latest updates

- **2026-07** — Appeared with Parexel’s Katie Connelly at DIA Global to discuss AI-enabled regulatory authoring and reported measurable improvements in submission speed, consistency, and quality.
- **2026-06** — Weave announced support for global submissions from a single source of truth, beginning with an EU Clinical Trial Application template and configurable structures for other jurisdictions.
- **2026-04** — Weave launched NDA workflow support designed with Parexel, extending the platform from IND preparation through approval-stage submissions.
- **2026-03** — Weave formed its first strategic advisory board with leaders connected to Boehringer Ingelheim, Takeda, Gilead Sciences, Serrado Capital, and Stanford University.
- **2026-01** — Published an article arguing that 2026 would mark regulatory AI’s shift from experimentation toward workflow transformation and demonstrable results.
- **2025-10** — Weave raised a $20 million Series A led by USVP, bringing disclosed total funding to $36 million.

## Links

- Website: https://weave.bio
- LinkedIn: https://www.linkedin.com/in/brandon-james-rice
- Twitter/X: https://twitter.com/weave_bio

---

Profile page: https://yespress.io/brandon-rice
Published by YesPress — https://yespress.io
Last updated: 2026-08-18